98%
921
2 minutes
20
Aims: Adherence to medical regimens, including medications and appointments, is a significant concern for adolescent populations that warrants behavioral interventions. Negative health behaviors during adolescence can persist into adulthood and lead to long-term negative health outcomes. Due to the limited availability and resources for behavioral self-management intervention, many youth do not receive evidence-based behavioral care and continue to struggle with managing their illness. Therefore, there is a need for easily accessible mHealth interventions targeting self-management in order to reduce health care barriers and provide more timely and effective behavioral care particularly during this developmental stage.
Methods: We provide a description of the design and methodology of the Self-Management Assistance for Recommended Treatment (SMART) IBD App randomized controlled pilot trial in pediatric inflammatory bowel disease (IBD) that aims to test the preliminary efficacy of the SMART IBD app compared to a usual care (UC) arm. Thirty participants 13-17 years of age will be recruited and randomized in the trial. Those randomized to the intervention arm will use the app for four weeks, each with one weekly challenge that focuses on self-management. Participants in both arms will complete baseline assessments, daily diaries for four weeks, and post-treatment assessments.
Conclusion: We hypothesize that participants in the intervention arm will experience clinically significant improvements in their self-management compared to those in the UC arm at the post-treatment assessment. Findings from the current study could provide initial evidence to support self-management interventions in adolescents with health conditions via mobile health apps, thereby reducing health care barriers and strains on institutional and nursing resources. Mobile health apps may also be a preferred avenue to disseminate interventions to adolescents.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11657775 | PMC |
http://dx.doi.org/10.1016/j.hctj.2023.100031 | DOI Listing |
Am J Bot
September 2025
Key Laboratory of Biodiversity and Environment on the Qinghai-Tibetan Plateau, Ministry of Education, School of Ecology and Environment, Xizang University, Lhasa, China.
Premise: The demographic histories of temperate plants in Northeast Asia in response to Quaternary climate oscillations have long been the focus of evolutionary biologists, but have rarely been studied in herbaceous plants. Here, we investigated the phylogeographic patterns of Mukdenia and Oresitrophe.
Methods: We sequenced two plastid regions for O.
RSC Adv
July 2025
Nursing Department, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine Hangzhou 310000 Zhejiang China
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), remains a challenging chronic disorder with complex pathophysiology and limited therapeutic options. Peptide-based therapeutics have emerged as promising alternatives, offering high specificity, favorable safety profiles, and unique biological activities compared to traditional treatments. However, challenges including enzymatic degradation, poor oral bioavailability, and instability hinder their clinical translation.
View Article and Find Full Text PDFClin Gastroenterol Hepatol
June 2025
Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Electronic address:
Background & Aims: Use of wearable technologies is increasing and may offer potential benefits in collecting actionable health data. We performed a scoping review on the use of wearable technologies in patients with inflammatory bowel disease (IBD).
Methods: The PubMed, Embase, and Scopus databases were searched until February 7, 2025, and original studies on the use of wearables in IBD were included.
J Colloid Interface Sci
December 2025
School of Food and Biological Engineering, Hefei University of Technology, Hefei 230009, PR China. Electronic address:
Inflammatory bowel disease (IBD), a chronic inflammatory gastrointestinal disease, is closely related to diverse inflammatory factors like reactive oxygen and nitrogen species (RONS) and cell-free DNA (cfDNA). Herein, tannic acid (TA) modified hafnium hydride nanosheets (HfH@TA NSs) with a thickness of 1-4 nm, prepared by liquid-phase exfoliation, were explored as a high-performance anti-inflammatory agent for IBD treatment. By virtue of the high specific surface area of two-dimensional structure, HfH@TA NSs can effectively not only scavenge RONS, but also eliminate cfDNA, thus inhibiting the pro-inflammatory responses.
View Article and Find Full Text PDFPeerJ
June 2025
School of Basic Medicine, Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China.
Background: Inflammatory bowel disease (IBD) is characterized by chronic inflammation. Ulcerative colitis (UC) is a subtype of IBD. The symptoms of UC include inflammation, damage to crypts, and ulceration.
View Article and Find Full Text PDF